Tatva Chintan Pharma Chem Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/if5zbop2ig9x29iaa5blc7a4.pdf

Key Takeaways


Demand & Volume Recovery

Chintan Shah: "100% confidence because we have orders on hand most of the things. So, there is not if and but. At least till December, we have very clear visibility of what we are getting into."

SDA: Volume Strength, Value Erosion

Chintan Shah: "In terms of volumes what we have committed, we are absolutely sure to meet those volume commitments. Unfortunately, not the value commitments."

New Product Commercialization Pipeline

Chintan Shah: "This is the first time. That's why I said in my speech that the significant development and achievement for us is to deliver a sample which meets with the customer specification."

Margins: The Recovery Path

Chintan Shah: "Why do you want to push our cost high unnecessary? No, no. jokes apart. This is not an overnight development. It's probably we have been working on this since probably 7 years, at least, maybe 8 years, if I may not be wrong."

Electrolyte & Energy Storage: The Next Leg


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth25% revenue growth for FY26FY26 full year
EBITDA margin20% margin, with Q-on-Q expansion through the yearFY26 full year; visibility at least until December
SDA volume growth40–70% volume/value growth, give or take a quarterFY26, with Euro 7 orders beginning October 2025
PASC commercializationTwo large agro intermediates executing orders; one small production block commercializingQ3 FY26 for large orders; January 2026 for small block
Photo-chlorination suppliesProduction from August, commercialization supplies from NovemberNovember–December 2025 orders placed
Electrolyte dispatchSecond approved product dispatched from plantWithin current quarter (Q1 FY26)
Pharma intermediate commercializationFirst products expected to begin commercializingAugust–September 2026
Semiconductor commercializationSlow commercialization begins, leading to full-scale2027 start; full-scale by 2029
Next financial year growth"Probably another 20% to 25% growth"FY27
Next financial year margin"About similar, 20% level"FY27
CapexAbout ₹110 croresFY26

Key Metrics

MetricQ1 FY26
Operating revenue₹116.9 cr, +11% YoY and +8% QoQ
EBITDA₹17.3 cr, +37% YoY and +94% QoQ
EBITDA margin14.8%, +287 bps YoY; COGS down 4.1% partly offset by other expenses up 1.2%
PBT₹9.1 cr vs ₹6.8 cr in Q1 FY25
PAT₹6.6 cr vs ₹5.2 cr in Q1 FY25
PAT margin5.7% vs 4.9% in Q1 FY25
EPS₹2.84 vs ₹2.23 in Q1 FY25
Exports₹83 cr, 71% of revenue vs 61% last quarter
Phase Transfer Catalyst revenue₹32.3 cr, +9% YoY and -17% QoQ
Structure Directing Agents revenue₹39.4 cr, +13% YoY and +14% QoQ
PASC and Electrolyte Salts revenue₹43.2 cr, +11% YoY and +32% QoQ
FY26 revenue growth guidance25%
FY26 EBITDA margin guidance20%
FY26 capex plan₹110 cr
Electrolyte Salts FY26 revenue guidance₹15–20 cr